• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

    2/14/23 1:45:55 PM ET
    $SELB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SELB alert in real time by email
    SC 13G/A 1 mangrove-selb123122a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Selecta Biosciences, Inc.

    (Name of Issuer)

     

    Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants

    (Title of Class of Securities)

     

    816212104

    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)

    x Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 2 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mangrove Partners Master Fund, Ltd.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    OO

     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants.
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 3 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Mangrove Partners
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Cayman Islands
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)(3) 
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    OO

     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 4 of 9 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Nathaniel August
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) x
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    9,387,677(1)(3)
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    9,387,677
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    9,387,677
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    5.97% (2)
    12
    TYPE OF REPORTING PERSON
     
    IN, HC
     
    (1) Includes 4,127,258 common shares obtainable upon exercise of Common Warrants
    (2) This percentage is calculated based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258
     


     

     

    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 5 of 9 Pages

     

    Item 1.(a) Name of Issuer

    Selecta Biosciences, Inc.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    65 Grove Street

    Watertown, MA 02472

    Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

    Mangrove Partners, a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

    Mangrove Partners Master Fund, Ltd., a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

    Nathaniel August, a United States citizen, is located at 645 Madison Avenue, 14th Floor, New York, New York 10022

    The shares of the Issuer which are the subject of this SCHEDULE 13G/A (the “Shares”) are held by the Master Fund. Beneficial ownership of the Shares is also claimed by (i) Mangrove Partners which serves as the investment manager of the Master Fund, and (ii) Nathaniel August who is the principal of Mangrove Partners.  

     

    Item 2.(d) Title of Class of Securities

    Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants (the “Common Stock”)

     

    Item 2.(e) CUSIP No.:

    816212104

     

    CUSIP No.  816212104
     SCHEDULE 13G/A
    Page 6 of 9 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) o An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨

    A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

          Not Applicable

     

    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 7 of 9 Pages

     

     

    Item 4. Ownership

    Information with respect to the Reporting Persons' ownership of the Common Stock as of December 31, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

    The amount beneficially owned by each Reporting Person is determined based on the sum of (i) 153,031,097 Shares outstanding as of November 3, 2022, based on information provided by the Issuer and (ii) 4,127,258 Shares issuable upon exercise of the Common Warrants, as the Issuer reported in its Form 10-Q filed with the SEC on November 3, 2022.

    The filing of this SCHEDULE 13G/A shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that are not directly owned by such Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    See disclosures in Item 2 and Exhibit I.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 8 of 9 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

     

     

    Mangrove Partners

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Mangrove Partners Master Fund, Ltd

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Nathaniel August

           
      By:  /s/ Nathaniel August
        Nathaniel August
           

     

     
    CUSIP No. 816212104
     SCHEDULE 13G/A
    Page 9 of 9 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: February 14, 2023

     

     

    Mangrove Partners

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Mangrove Partners Master Fund, Ltd

           
      By:  /s/ Nathaniel August
        Nathaniel August, Director
           
     

    Nathaniel August

           
      By:  /s/ Nathaniel August
        Nathaniel August
           
    Get the next $SELB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SELB

    DatePrice TargetRatingAnalyst
    8/18/2023$1.00Outperform → Market Perform
    SVB Securities
    6/14/2022$6.00 → $5.00Buy
    Needham
    6/6/2022$7.00Outperform
    SVB Leerink
    11/1/2021$6.00 → $7.00Buy
    Needham
    More analyst ratings

    $SELB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Selecta Biosciences downgraded by SVB Securities with a new price target

      SVB Securities downgraded Selecta Biosciences from Outperform to Market Perform and set a new price target of $1.00

      8/18/23 7:37:44 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Selecta Biosciences with a new price target

      Needham reiterated coverage of Selecta Biosciences with a rating of Buy and set a new price target of $5.00 from $6.00 previously

      6/14/22 7:48:06 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on Selecta Biosciences with a new price target

      SVB Leerink initiated coverage of Selecta Biosciences with a rating of Outperform and set a new price target of $7.00

      6/6/22 7:48:05 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Singer Michael was granted 178,000 units of Common Stock, increasing direct ownership by 162% to 288,123 units (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:12:27 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Davis Blaine was granted 2,424,000 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jewell Christopher M was granted 778,200 units of Common Stock (SEC Form 4)

      4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)

      1/4/24 5:08:06 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $SELB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SELB
    Financials

    Live finance-specific insights

    See more

    $SELB
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/14/24 12:38:55 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Selecta Biosciences Inc. (Amendment)

      SC 13G/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 5:13:58 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Selecta Biosciences Inc.

      SC 13G - Cartesian Therapeutics, Inc. (0001453687) (Subject)

      2/9/24 8:50:19 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity

      Topline data from Phase 2b study of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy in myasthenia gravis (MG) remains on track for mid-2024 Positive 12-month follow-up data from Phase 2a study in MG reported today; durable depletion of autoantibodies and clinically meaningful improvements in MG severity scores observed approximately 10 months after last infusion Phase 2 study of Descartes-08 in systemic lupus erythematosus expected to initiate in 1H24 Clinical pipeline expanded following recent IND clearance for Descartes-15, a next-generation mRNA CAR-T product candidate Approximately $118M pro forma cash and cash equivalents as of D

      1/8/24 7:10:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis

      Durable depletion of autoantibodies and clinically meaningful improvements in myasthenia gravis (MG) severity scores observed after one-year follow-up period without need for lymphodepleting chemotherapy Descartes-08 observed to be well tolerated following administration in outpatient setting Publication is in peer review and available on the preprint server, medRxiv Topline data from Phase 2b placebo-controlled study continues to be expected in mid-2024 GAITHERSBURG, Md., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC), ("the Company") a clinical-stage biotechnology company pioneering mRNA cell therap

      1/8/24 7:00:00 AM ET
      $RNAC
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Merger with Cartesian Therapeutics

      – Merger creates a fully integrated, publicly traded company pioneering RNA cell therapy for the treatment of autoimmune disease – – Cartesian's wholly owned pipeline includes a Phase 2 lead asset, Descartes-08, for which deep and durable responses have been observed in patients with myasthenia gravis (MG) – – Multiple near-term catalysts, including data from the Phase 2b study of Descartes-08 in MG expected in mid-2024 and initiation of multiple studies in additional autoimmune indications – – Combined company is expected to have a pro forma cash balance over $110 million at close, including $60.25 million from concurrent private financing; expected cash runway through Phase 3 developmen

      11/13/23 8:05:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics

      – Company to continue focusing on advancement of SEL-212, a potential treatment for chronic refractory gout; Biologics License Application (BLA) filing on track for 1H 2024 – – Company to suspend further investment in majority of pipeline; evaluating potential licensing and corporate development initiatives for pipeline assets – – Cash, cash equivalents, restricted cash, and marketable securities of $115.0 million as of June 30, 2023 expected to fund operations into 2027 – – Selecta to host conference call today at 8:30 AM ET – WATERTOWN, Mass., Aug. 17, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its cli

      8/17/23 7:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update

      - Company to implement capital prioritization initiative, extending cash runway to 2H-2025 - - $127.5 million in cash, cash equivalents, restricted cash, and marketable securities as of March 31, 2023 - - Reported positive data from Phase 3 DISSOLVE program of SEL-212 in chronic refractory gout; BLA filing expected in 1H 2024 - - Selecta to host conference call today at 8:30 AM ET - WATERTOWN, Mass., May 04, 2023 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the first quarter

      5/4/23 7:30:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

      WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. "Blaine is a highly accomplished biopharmaceutical executive with proven financial and business development expertise," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta. "We are preparing for a number of key potential milestones across our pipeline

      11/28/22 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Surface Oncology Appoints Carsten Brunn to Board of Directors

      CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad

      6/29/22 7:00:00 AM ET
      $SELB
      $SURF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Selecta Biosciences Announces Appointment of Kevin Tan as Chief Financial Officer

      WATERTOWN, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced the appointment of Kevin Tan as chief financial officer. "Kevin's deep financial expertise and experience in the gene therapy and rare disease landscape makes him an ideal fit for Selecta's executive team," said Carsten Brunn, Ph.D., president and chief executive officer of Selecta. "This is an exciting time for Selecta on the heels of our recent collaboration with Cyrus Biotechnology to unlock a new generation of inno

      9/20/21 8:00:00 AM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SELB
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Selecta Biosciences Inc.

      DEFA14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 5:27:24 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Selecta Biosciences Inc.

      DEF 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      2/14/24 4:42:00 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by Selecta Biosciences Inc.

      PRE 14A - Cartesian Therapeutics, Inc. (0001453687) (Filer)

      1/31/24 4:30:29 PM ET
      $SELB
      Biotechnology: Pharmaceutical Preparations
      Health Care